Table 3.
Crude IRs and HRs for overall and specific cancers in AK patients compared with controls with and without adjustment for hypertension, diabetes mellitus, dyslipidemia, habitat and income status.
| Cancer | Crude IR per 1000 | HR (95% CI) without adjustment | HR (95% CI) with adjustment* | |
|---|---|---|---|---|
| Actinic keratosis | Controls | |||
| Overall cancer | 14.40 | 10.11 | 1.43 (1.38, 1.48) | 1.43 (1.38, 1.47) |
| Skin cancer | 0.19 | 0.06 | 3.43 (2.48, 4.75) | 3.43 (2.47, 4.75) |
| Oral cavity and pharyngeal cancer | 0.30 | 0.15 | 1.99 (1.57, 2.52) | 1.99 (1.57, 2.52) |
| Lymphoma | 0.34 | 0.21 | 1.60 (1.29, 1.99) | 1.59 (1.28, 1.96) |
| Leukemia | 0.21 | 0.16 | 1.35 (1.03, 1.76) | 1.35 (1.03, 1.77) |
| Prostate cancer¶ | 3.31 | 2.43 | 1.36 (1.22, 1.52) | 1.35 (1.21, 1.51) |
| Renal cancer | 0.28 | 0.22 | 1.30 (1.03, 1.63) | 1.29 (1.02, 1.63) |
| Multiple myeloma | 0.08 | 0.12 | 0.65 (0.43, 0.98) | 0.65 (0.43, 0.97) |
| Liver cancer | 1.32 | 1.09 | 1.22 (1.09, 1.35) | 1.21 (1.09, 1.35) |
| Thyroid cancer | 0.81 | 0.67 | 1.21 (1.06, 1.39) | 1.20 (1.05, 1.38) |
| Laryngeal cancer | 0.08 | 0.07 | 1.15 (0.75, 1.74) | 1.15 (0.76, 1.75) |
| Esophageal cancer | 0.15 | 0.13 | 1.14 (0.84, 1.55) | 1.13 (0.83, 1.54) |
| Gastric cancer | 1.83 | 1.62 | 1.13 (1.03, 1.24) | 1.13 (1.03, 1.23) |
| Colorectal cancer | 2.11 | 2.05 | 1.03 (0.95, 1.12) | 1.03 (0.94, 1.11) |
| Pancreatic cancer | 1.00 | 0.86 | 1.17 (1.03, 1.32) | 1.16 (0.97, 1.17) |
| Biliary cancer | 0.50 | 0.53 | 0.94 (0.79, 1.11) | 0.94 (0.79, 1.11) |
| Lung cancer | 1.71 | 1.61 | 1.07 (0.97, 1.17) | 1.06 (0.97, 1.17) |
| Bladder cancer | 0.46 | 0.40 | 1.17 (0.98, 1.40) | 1.17 (0.98, 1.40) |
| Cancer of central nervous system | 0.22 | 0.17 | 1.30 (1.00, 1.68) | 1.29 (0.99, 1.68) |
| Breast cancer† | 0.94 | 0.88 | 1.08 (0.92, 1.26) | 1.08 (0.92, 1.26) |
| Uterine cervical cancer† | 0.26 | 0.25 | 1.02 (0.75, 1.37) | 1.02 (0.75, 1.37) |
| Uterine corpus cancer† | 0.19 | 0.16 | 1.19 (0.83, 1.71) | 1.21 (0.85, 1.74) |
| Ovarian cancer† | 0.31 | 0.28 | 1.08 (0.82, 1.42) | 1.08 (0.82, 1.42) |
| Testicular cancer¶ | 0.04 | 0.05 | 0.86 (0.33, 2.23) | 0.86 (0.33, 2.21) |
IR incidence rate, HR hazard ratio, CI confidence interval.
*Adjustment for diabetes mellitus, hypertension, dyslipidemia, habitat, and income status.
†Female malignancies were analyzed in 95,570 females.
¶Male malignancies were analyzed in 45,800 males.